MODERNA INC

NASDAQ: MRNA (Moderna, Inc.)

最近更新时间: 2天之前, 5:24AM

196.79

-10.01 (-4.84%)

前收盘价格 206.80
成交量 6,912,807
价格/销量 (P/S) 32.54
股市价格/股市净资产 (P/B) 12.22
52周波幅
22.28 (-88%) — 280.80 (42%)
营业毛利率 -105.67%
营业利益率 (TTM) -972.22%
稀释每股收益 (EPS TTM) -8.73
季度收入增长率 (YOY) -35.30%
总债务/股东权益 (D/E MRQ) 7.40%
流动比率 (MRQ) 4.22
营业现金流 (OCF TTM) -3.05 B
杠杆自由现金流 (LFCF TTM) -3.20 B
资产报酬率 (ROA TTM) -15.84%
股东权益报酬率 (ROE TTM) -29.34%

AIStockmoo 评分

-0.3
中立已持续3天
资本回报低于资本成本。资本回报下降。 参考
负债低。盈利能力弱。短期流动性充足。现金流为负。 参考
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
持仓估值 参考 NA
风险溢价 参考 NA
市场估值 参考 NA
过去一年呈上升趋势。股价远低于52周高点。 参考
上升趋势:股价位于均线之上,均线向上。股价接近均线。 参考
来自我们对走势图的 AI 技术分析。 参考 NA
K线形态 参考 NA
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻大多正面。 参考
持仓情绪 参考 NA
机构在最新13F申报中净+0.11%的股份:677家增持,357家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化-15.2%,回补天数1.8天(FINRA)。 参考
内部交易活动 参考 NA
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向不一,评分因此减弱。
每股盈利大多下降。近年曾亏损。 参考
高于中期趋势线。 参考
股价高于其52周平均水平。5年来下跌。 参考
短期动能下降。 参考
股价接近支撑位。支撑与阻力水平趋升。 参考
最终评分 -0.28
全部展开

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看涨
Biotechnology (全球的) 混合的 看涨
股票 Moderna, Inc. 混合的 看涨

相关股票

股票 市值 DY P/E(TTM) P/B 评分
MRNA - - - 12.22 -0.3
KOD 6 B - - 500.31 0.0
PTCT 5 B - - - 0.0
ABCL 3 B - - 3.39 -0.5
DNLI 3 B - - 3.18 -2.1
CELC 3 B - - 83.17 -1.5

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 7.28%
机构持股比例 73.67%

该时间范围内无数据。

该时间范围内无数据。

机构

机构持股比例: 90.07%

持仓变动 机构数 股数
增持 677 36,557,615
减持 357 40,275,883
新建仓 353 5,764,990
清仓 76 1,618,068

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 33,191,285 1.8
15 Oct 2026 32,603,398 1.8
30 Sep 2026 30,863,202 1.8
15 Sep 2026 32,872,787 2.5
31 Aug 2026 39,151,532 1.0
14 Aug 2026 52,809,184 9.1

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

21 正面 8 负面 10 中性
日期 类型 细节
19 Nov 2026 Yahoo Finance While Moderna sank 17%, this generic drugmaker quietly jumped 64%
Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
19 Nov 2026 Yahoo Finance Moderna (MRNA) Dropped, So What Is Behind The Latest Attention?
Moderna (MRNA) just reworked its debt deal, cutting interest margins on existing and delayed draw term loans by 0.75 percentage points, and pushing key maturities and borrowing availability further into the next decade. Moderna sits at US$196.79 after a sharp 1-day share price return of down 4.84%…
19 Nov 2026 Yahoo Finance Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.
Moderna's melanoma vaccine plus Keytruda cut the risk of recurrence or death by 42% in Phase 3, yet the stock sank. Here's why.
18 Nov 2026 Yahoo Finance Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity
Moderna (NASDAQ:MRNA) is preparing to file a U.S. application for its individualized cancer therapy intismeran by year-end, as executives outlined manufacturing plans and upcoming trial results following positive phase III melanoma data. At a Jefferies investor session, Head of Investor Relations L…
17 Nov 2026 Yahoo Finance JPMorgan Still Sees Moderna Overvalued Despite Raising Its Target
The firm sees a gap between Moderna's $87.1 billion market value and what its pipeline can justify…
17 Nov 2026 Yahoo Finance Moderna's INT Outlook Strengthens After Phase 3 Melanoma Data, Morgan Stanley Says
Moderna's (MRNA) phase 3 adjuvant melanoma data establishes clinical proof of concept for individual…
17 Nov 2026 Yahoo Finance At $215, Moderna Stock Already Prices In A Comeback
Today's big story: Could Nvidia Stock Fall 50%? Follow The Cash.
16 Nov 2026 Yahoo Finance Is Moderna's Cancer Vaccine a Game Changer for the Stock?
The healthcare stock has hit multi-year highs this year amid positive results from its personalized cancer vaccine.
16 Nov 2026 Yahoo Finance Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive
One melanoma headline turned a $63 stock into a market darling, and Moderna's CEO just told Jim Cramer when patients could get the shot. Does the price already bake in the cancer breakthrough, or is the next catalyst still ahead?
16 Nov 2026 Yahoo Finance Proshares Trust (TQQQ) Buys $72.9 Million More Moderna on Nov. 12
The 3x leveraged Nasdaq-100 fund added a $72.9 million Moderna stake while trimming 100 positions and net selling $101.1 million.
16 Nov 2026 Yahoo Finance What Invesco S&P 500 Equal Weight ETF (RSP) Bought: Moderna Leads on Nov. 12
The fund added $319.5 million in gross purchases, lifting all 503 positions and making no sales.
16 Nov 2026 Yahoo Finance Moderna (MRNA) Sees $109.7 Million in Net ETF Buying on Nov. 12
ETFs bought $109.7 million of Moderna stock on Thursday, Nov. 12…
14 Nov 2026 Yahoo Finance Moderna Sinks 12% in a Week. Bancel Wants an FDA Filing “Before the End of the Year”
Key TakeawaysModerna fell 12% in the week to Nov. 13 after guiding to about $4 billion or more of cash costs a year through 2030, mostly for cancer drugs.
14 Nov 2026 Yahoo Finance Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
Axsome's revenue has climbed about 54% while Moderna's net losses run deep, but a steep valuation gap may tip the scales for patient investors.
13 Nov 2026 Yahoo Finance The Single Most Important Metric For Moderna Stock
For questions about this article or underlying research, email [email protected].
13 Nov 2026 Yahoo Finance Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
MRNA shares fall as 2027 cost projections raise concerns, while limited visibility into future revenue growth weighs on investor sentiment.
13 Nov 2026 Yahoo Finance What Invesco S&P 500 Equal Weight ETF (RSP) Sold: Moderna Leads on Nov. 11
The $105.70 billion fund sold $93.1 million of stock on Wednesday, trimming 502 positions and adding to none.
12 Nov 2026 Yahoo Finance GSK (LSE:GSK) Settles Key Vaccine Patent Case And Wins Broad Europe Injunction
GSK (LSE:GSK) reached a cross-licensing agreement with Moderna resolving their COVID-19 vaccine patent dispute in Europe. The pharma group secured a significant injunction against Pfizer-BioNTech covering liposome delivery technology used in RNA vaccines across multiple European markets. Ongoing…
12 Nov 2026 Yahoo Finance Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook
Moderna (NASDAQ:MRNA) is preparing to seek U.S. approval of its individualized cancer treatment intismeran by year-end, with executives aiming for a 2027 launch alongside partner Merck if regulators approve the therapy. At an investor event in Marlborough, Massachusetts, company leaders highlighted…
12 Nov 2026 Yahoo Finance Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes.
The biotech plans to reinvest in its pipeline, particularly oncology treatments like its personalized cancer vaccine.
12 Nov 2026 Yahoo Finance Moderna Sinks 7% as Analyst Day Cancer Push Brings “$4 Billion in Cash Costs in 2027”
Key TakeawaysModerna shares fell 7% today after the company guided to cash costs of about $4 billion in 2027 and $4 billion to $4. 5 billion a year through 2030, mostly for oncology.
12 Nov 2026 Yahoo Finance Why Is Moderna (MRNA) Joining A Global Benchmark And Publishing New Vaccine Data?
Moderna (NasdaqGS:MRNA) is scheduled to join the MSCI World Index in November 2026, which would add the stock to a major global benchmark. The biotech group reported publication of real world data on its mNEXSPIKE COVID-19 vaccine in older adults in a peer reviewed journal. The new study compared…
12 Nov 2026 Yahoo Finance Why Moderna Stock Dropped on Thursday
Moderna promised 20% sales growth in 2026 -- but Wall Street wants 24%.
12 Nov 2026 Yahoo Finance MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
Moderna's 3% post-earnings gain reflects stronger overseas COVID-19 sales and higher 2026 guidance, while oncology advances offer growth potential.
12 Nov 2026 Yahoo Finance Merck’s Keytruda Combo Cut Melanoma Recurrence or Death Risk 42%. What the February 2 Report Has to Prove
Key TakeawaysModerna said on Nov. 6 that it and Merck plan to file intismeran, which cut melanoma recurrence or death risk 42% with Keytruda, this year.
12 Nov 2026 Yahoo Finance Moderna Raises 2026 Revenue Growth Forecast to 15%–25% and Reports Progress in Cancer Vaccine Development
Moderna, Inc. (NASDAQ:MRNA) increased its 2026 revenue growth forecast to between 15% and 25%, compared with its previous outlook of up to 10%, as the biotechnology company outlined financial expectations and clinical development updates during its 2026 Analyst Day in Cambridge, Massachusetts.
12 Nov 2026 Yahoo Finance Moderna Outlines Next Phase of Growth at Analyst Day
Moderna also provided updates on commercial growth, oncology pipeline progress, manufacturing readiness and mid-term financial objectives."We founded Moderna on the belief that mRNA could transform medicine, and over the past decade we have built a powerful platform to realize that vision," said…
12 Nov 2026 Yahoo Finance What Invesco S&P 500 Equal Weight ETF (RSP) Bought: Moderna Leads on Nov. 10
The fund added $739.1 million in net buys against $757.9 million gross traded, lifting 501 positions while trimming just one.
11 Nov 2026 Yahoo Finance Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine
Analysts have placed intismeran central to Moderna’s long-term growth beyond infectious diseases.
11 Nov 2026 Yahoo Finance Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
Real-world analysis of more than 294,000 U. Veterans aged 65 and older found mNEXSPIKE was associated with a 35…
11 Nov 2026 Yahoo Finance Moderna Stock Jumped 10% in 5 Sessions: Take Profits, or Buy More?
Key TakeawaysModerna (MRNA) stock gained approximately 9. 8% over five trading sessions, closing at $250…
10 Nov 2026 Yahoo Finance Why is Moderna (MRNA) stock soaring today
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after the company reported third-quarter 2026 financial results, with revenue rising 29% to $1.3 billion, and raised its full-year revenue growth forecast.
10 Nov 2026 Yahoo Finance Moderna to Present at Upcoming Conference in November 2026
CAMBRIDGE, MA / ACCESS Newswire / November 10, 2026 / (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:Jefferies Global Health Care Conference, on Wednesday, November 18th 11:00am GMTA live webcast of each of these presentations will be available under…
10 Nov 2026 Yahoo Finance “More Cancers Than Melanoma”: Moderna Is Up 750% in 2026. Take Profits, or Buy More?
Key TakeawaysModerna stock is up 750% in 2026, mostly on its melanoma vaccine with Merck, which succeeded in Phase 3. Third-quarter revenue rose 29% on COVID deals abroad, while Pfizer’s rival shot sold less.
10 Nov 2026 Yahoo Finance What Invesco S&P 500 Equal Weight ETF (RSP) Bought: Moderna Leads on Nov. 6
The fund added $291.5 million in gross purchases on Friday, increasing all 503 positions and selling nothing.
09 Nov 2026 Yahoo Finance Why Did U, MRNA, ABNB Stocks Surge To 52-Week Highs Today?
Investors showed interest in AI gaming tools, advances in cancer vaccines and future business growth.
09 Nov 2026 Yahoo Finance Is Moderna (MRNA) Priced For Too Much Sales Growth?
Moderna has turned into one of the market’s sharpest movers, and after such a powerful run, the key issue for you is whether the current share price still lines up with what its sales can support. A stock can move very quickly when sentiment swings on new data or approvals, so the question is how…
09 Nov 2026 Yahoo Finance Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
Revenue for the vaccine maker rose sharply in the third quarter, but it was largely due to COVID sales, which have been down significantly over the past five years.
06 Nov 2026 CNBC Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
显示更多

近期信号 K线形态与EMA交叉

▼ EMA看跌交叉 2个交易日前 · 17 Nov
短期 · EMA 7/20
7日EMA下穿20日EMA:短期动能转弱。

技术形态 中期

趋势排列
斜率
入场位置
成交量
上升趋势:股价位于均线之上,均线向上。股价接近均线。
最近支撑: 172.09 – 187.85 · 强 · 多次测试,可能失守
最近阻力: 204.33 – 216.79 · 强

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

风险 / 回报
TP1:
TP2:

以入场价计算,止损的亏损相对每个目标价的盈利。通常追求 2 或以上的比率。

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票